• Acurion

  Participated · Seed · Apr 2026

  Acurion develops the OncoGaze™ platform, an AI-powered image analysis system that detects clinically actionable cancer biomarkers from routine pathology slides. The technology is positioned to extract biomarker insights without requiring additional tissue or specialized molecular testing. Acurion builds on foundational research from co-founder and CSO Ludmil Alexandrov, Ph.D., and has published in leading oncology and scientific journals while expanding clinical collaborations. The company says it is moving from validation toward deployment and is focusing on clinical and regulatory milestones. Acurion closed an oversubscribed $4.3 million seed round to fund clinical validation, platform development, regulatory preparation, and commercialization. The company expects to announce further clinical collaborations and regulatory progress in the coming months.

• Degron Therapeutics

  Led · Series A · Dec 2023

  Degron Therapeutics builds molecular glue degrader medicines via its proprietary GlueXplorer® discovery platform, which has generated more than 10,000 structurally differentiated MGD compounds across over 150 novel non-IMiDs cores. Its lead program, DEG6498, is a first-in-class HuR molecular glue degrader that entered a Phase 1 first-in-human study with first patient dosed in November 2025 and has IND clearances in the U.S. and China. The company’s pipeline spans oncology, inflammation, metabolic disorders, and rare diseases, and includes two immunology programs being advanced toward development candidate/IND stage in 2026. Degron was founded in 2021 and is headquartered in Shanghai, with offices in Hangzhou and San Diego. The company has partnered with external pharmaceutical companies, including Takeda, to expand MGD R&D.

• Chimera Bioengineering

  Led · Equity · Apr 2022

  Chimera Bioengineering is developing the GOLD Platform to improve control, reduce toxicity, and increase efficacy of engineered CAR‑T cell therapies for solid tumors. The company engineers T cells to selectively activate when they encounter tumor cells and deliver payloads to counteract the suppressive tumor microenvironment. Preclinical data cited by the BRACE program support the platform’s potential to apply CAR‑T curative potential to solid tumors. Chimera is based in Johnson & Johnson Innovation – JLABS in South San Francisco, California. As BRACE Award winner, the company gained access to AFCR’s network of cancer experts, advisors and visibility that the program provides. Chimera says it will leverage that support and new capital to advance its platform toward transformative therapies for cancer patients in Asia and beyond.

No current team members are available.